該Biotinylated Human CD3E&CD3G/CD3 epsilon&CD3 gamma Protein (Primary Amine Labeling)(Biotinylated Human CD3E&CD3G/CD3 epsilon&CD3 gamma Protein (Primary Amine Labeling))背景資料,請查看產品使用說明書或者咨詢艾美捷科技
序列
該Biotinylated Human CD3E&CD3G/CD3 epsilon&CD3 gamma Protein (Primary Amine Labeling)(Biotinylated Human CD3E&CD3G/CD3 epsilon&CD3 gamma Protein (Primary Amine Labeling))序列,請查看產品使用說明書或者咨詢艾美捷科技
來源宿主
該Biotinylated Human CD3E&CD3G/CD3 epsilon&CD3 gamma Protein (Primary Amine Labeling)(Biotinylated Human CD3E&CD3G/CD3 epsilon&CD3 gamma Protein (Primary Amine Labeling))來源宿主,請查看產品使用說明書或者咨詢艾美捷科技
溶解建議
該Biotinylated Human CD3E&CD3G/CD3 epsilon&CD3 gamma Protein (Primary Amine Labeling)(Biotinylated Human CD3E&CD3G/CD3 epsilon&CD3 gamma Protein (Primary Amine Labeling))溶解建議,請查看產品使用說明書或者咨詢艾美捷科技
保存建議
該Biotinylated Human CD3E&CD3G/CD3 epsilon&CD3 gamma Protein (Primary Amine Labeling)(Biotinylated Human CD3E&CD3G/CD3 epsilon&CD3 gamma Protein (Primary Amine Labeling))保存建議,請查看產品使用說明書或者咨詢艾美捷科技
其他
Kactus Biosystems(愷佧生物科技(上海)有限公司)成立于2018年3月,是一家以研發(fā)為驅動的創(chuàng)新型靶點蛋白和治療用蛋白酶類生物高科技公司,主要專注于免疫治療、細胞和基因治療以及mRNA治療市場。愷佧生物擁有專屬的新型功能重組蛋白和高活性蛋白酶類研發(fā)生產平臺Structure Aided Design and Multiplex Screening(SAMSTM),聚焦于全球創(chuàng)新藥研發(fā)企業(yè)客戶,提供基于結構設計的功能靶點蛋白和用于細胞和基因治療以及mRNA疫苗生產過程中需要的關鍵蛋白酶原料。